Research Insight
New potential drug targets discovered for preventing prostate cancer cell growth
Researchers from VTT Technical Research Centre of Finland and the University of Turku have discovered four metabolic enzymes regulating prostate cancer cell growth. Inhibition of these enzymes prevents prostate cancer cell growth in cultured cells. This knowledge can be...
Research Insight
Manhattan Research’s ePharma Consumer study provides in-depth info about pharma product websites
Pharmaceutical and healthcare market research company Manhattan Research recently released the ePharma Consumer® v10.0 study, which explores the online behaviors of ePharma Consumers, or U.S. consumers using the Internet for prescription drug information. The study...
Research Insight
Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol. Allopurinol currently accounts for greater than 90% of the unit...
Research Insight
Pro-Pharmaceuticals and Mount Sinai annouced New Liver Fibrosis Research Collaboration
Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several...
Research Insight
New data show potential for Novartis Meningitis B vaccine candidate to cover majority of diverse meningococcal serogroup B strains
New data demonstrated that antibodies induced by Novartis Vaccines investigational, four component, Meningococcal Serogroup B Vaccine (4CMenB) killed the majority of a collection of geographically and genetically diverse meningococcal serogroup B (MenB) strains. The strain coverage research findings were...
Research Insight
University of Rochester Spearheads FDA Initiative to Speed Development of New Therapies
Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications – opioids and non-steroidal anti-inflammatory drugs – have major drawbacks, including the potential for misuse and abuse...
Research Insight
Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
Genentech, Inc., a member of the Roche Group, and Biogen Idec announced 24-week results1 from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form2Â of the disease. Ocrelizumab demonstrated a significant...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read